Abivax reports ulcerative colitis data

Thursday 3 September 2020
Country

France

ABX464, a small molecule drug being investigated for ulcerative colitis, generated positive data in patients who completed a second year of treatment, the developer Abivax SA announced on 2 September. The Phase 2a maintenance study showed that 69% of patients were in clinical remission and 94% benefited from a clinical response at the end of the second year. Twenty-two patients were initially enrolled in the study in which ABX464 was administered once daily at a dose of 50 mg.